

10/559852

IAP9 Rec'd PCT/PTO 07 DEC 2005

"Express Mail" mailing label number	EL 832 895 713 US
Date of Deposit	07 Dec. 2005
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
QUEEN Thomas	Queen Thomas
Printed Name	Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: AMEGADZIE Albert Kudzovi
For: TACHYKININ RECEPTOR ANTAGONISTS
Docket No.: X-15590

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Applicant notes that EP 1 176 144, which was cited in the International Search Report as a category "A" document, has a US equivalent patent document (US 6,407,106), which is being submitted herewith. Also with this Information Disclosure Statement, an English translation of foreign patent document FR 2 329 275 is being submitted.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicant submits that no additional fee is required.

Applicant requests consideration of this information.

Respectfully submitted,



Manisha A. Desai
Attorney for Applicant
Registration No. 43,585
Telephone: 317-433-5333

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

1 December 2005
Rev. 6/05

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15590	Serial No. 10/559852
	Applicants Amegadzie, et al.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 5,998,444	12-07-1999	Russell	
	AB	US 6,060,478	05-09-2000	Gilligan, et al.	
	AC	US 6,407,106	06-18-2002	Jasserand, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 95/11880	04-05-1995			
	BB	WO 97/40025	10-30-1997			
	BC	WO 99/07677	02-18-1999			
	BD	WO 01/44200 A2	06-21-2001			
	BE	WO 02/08232 A1	01-31-2002			
	BF	WO 03/091226 A1	11-06-2003			
	BG	WO 03/091227 A1	11-06-2003			
	BH	EP 0 699 665 A1	03-06-1996			
	BI	JP P2002-123925A	04-26-2002			X
	BJ	FR 76 32136	10-25-1976			X

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	ABU-ORABI, et al., "Dipolar Cycloaddition Reactions of Organic Azides," <u>J. Heterocyclic Chem.</u> , 26, pp. 1461-1468 (1989).	
	CB	AL-TALIB, et al., "Synthesis of 4,5-Bis-[5-aryl-1,3,4-oxadiazol-2-YL]-1-Substituted Benzyl-1,2,3-Triazoles," <u>Indian J. of Heterocyclic Chem.</u> , 8, pp. 183-188 (1999).	

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15590	Serial No. 10/559852
	Applicants Amegadzie, et al.	
	Filing Date	Group

	CC	BIAGI, et al., "N<6>-Cycloalkyl-2-Phenyl-3-Deaza-8-Azaad Nines: A New Class of A1 Adenosine Receptor Ligands. A Comparison With the Corresponding Adenines and 8-Azaadenines", <u>European J. of Medicinal Chemistry</u> , 38, pp. 983-990 (2003)	
	CD	COTTRELL, et al., "An Improved Procedure for the Preparation of 1-Benzyl-1H-1,2,3-triazoles from Benzyl Azides," <u>J. Heterocyclic Chem.</u> , 28, pp. 301-304 (1990).	
	CE	HAJJAJI, et al., "Synthesis and Evaluation of the Inhibitor Effect of a New Class of Triazole Compounds," <u>Progress in Organic Coatings</u> , 38, pp. 207-212 (2000).	
	CF	IVANOV, et al., "Synthesis of 1,2,3-Triazolo '5,4-e!-1,4-diazepine", <u>J. of Organic Chemistry of the USSR</u> , XP009037402, 25:9, pp. 1785-1789 (1989)	
	CG	KATRITZKY, et al., "Synthesis of C-Carbamoyl-1,2,3-triazoles by Microwave-Induced 1,3-Dipolar Cycloaddition of Organic Azides to Acetylenic Amides", <u>J. Organ. Chem.</u> , XP002299474, 67, pp. 9077-9079 (2002)	
	CH	KATRITZKY, et al., "1,3-Dipolar Cycloadditions of Organic Azides to Ester or Benzotriazolylcarbonyl Activated Acetylenic Amides", <u>ARKIVOC</u> , 15, XP002299475, 15, pp. 47-64 (2003)	
	CI	L'ABBÉ, et al., "Synthesis and Thermolysis of 4-Substituted 5-Azido-1-Phenyl-1,2,3-Triazoles", <u>Tetrahedron</u> , XP001153468, 44:12, pp. 3617-3626 (1988).	
	CJ	THEOCHARIS, et al., "Synthesis and Spectral Data of 4,5-Bis[5-aryl-1,3,4-oxadiazol-2-yl]-1-benzyl-1,2,3-triazoles," <u>J. Heterocyclic Chem</u> , 27, pp. 1685-1688 (1990).	
	CK	ACS Chemcats 2001:1613994, Publication Date 01-07-2001, Order No. AN-666/14744011, CAS Registry No. 354780-46-4.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.